We are Bios Partners, a venture capital firm based in Dallas/Fort Worth.
We invest in early seed opportunities as well as later stage growth companies, with a focus on biotech and medical devices companies.
Disrupting the geographic favoritism
There is a disproportionate amount of capital in regions traditionally known for venture capital, including the West Coast and New England. Due to this “Geographic Favoritism”, opportunities with equally compelling science across the South, South Eastern and the Central United States, are overlooked and undervalued.
Bios Partners believes in investment activism; great science may never meet the marketplace due to traditionally scientifically experienced early stage CEOs lack of business acumen.
80 years of collective experience
Bios Partners has a combined 80 years of experience in hedge funds, private equity, clinical drug development and public pharma/biotech analysis to
fill the CEO’s experiential void.
Our Map Of Therapeutics...
Lung Therapeutics LTI-01 (Phase 2)
Lung Therapeutics LTI-02 (Pre-IND)
Lung Therapeutics LTI-03 (Pre-IND)
Azitra AZT-01 (Pre-IND)
Cognition Therapeutics CT-1812 (Phase 1)
Encore Vision EV-06 (Phase 2)
Lantern Pharma Tavocept (Phase 2)
Lantern Pharma Irofluven (Phase 2)
Lantern Pharma LP-184 (Pre-IND)
Actuate 9-ING-41 (Pre-IND)
Abilitech’s Abilitech Exo (Development)
410 Medical’s Lifeflow (Commercial)